[go: up one dir, main page]

TNSN06368A1 - 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines - Google Patents

3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines

Info

Publication number
TNSN06368A1
TNSN06368A1 TNP2006000368A TNSN06368A TNSN06368A1 TN SN06368 A1 TNSN06368 A1 TN SN06368A1 TN P2006000368 A TNP2006000368 A TN P2006000368A TN SN06368 A TNSN06368 A TN SN06368A TN SN06368 A1 TNSN06368 A1 TN SN06368A1
Authority
TN
Tunisia
Prior art keywords
heteroarylcyclohexylamino
cyclopentanecarboxamides
modulators
chemokine receptors
des
Prior art date
Application number
TNP2006000368A
Other languages
English (en)
Inventor
Changsheng Zheng
Hao Feng
Michael Xia
Rajan Anand
Joseph Glenn
Brian Metcalf
Chu-Biao Xue
Ganfeng Cao
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of TNSN06368A1 publication Critical patent/TNSN06368A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE DES COMPOSES DE FORMULE (I) : QUI SONT DES MODULATEURS DE RECEPTEURS DE CHIMIOKINES. LES COMPOSES DE LA PRESENTE INVENTION, ET DES COMPOSITIONS LES CONTENANT, SONT UTILES DANS LE TRAITEMENT DE MALADIES EN RAPPORT AVEC L'EXPRESSION ET/OU L'ACTIVITE DE RECEPTEURS DE CHIMIOKINES.
TNP2006000368A 2004-05-11 2006-11-10 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines TNSN06368A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56994704P 2004-05-11 2004-05-11
PCT/US2005/016318 WO2005115392A2 (fr) 2004-05-11 2005-05-10 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides utilises comme modulateurs des recepteurs de la chimiokine

Publications (1)

Publication Number Publication Date
TNSN06368A1 true TNSN06368A1 (fr) 2008-02-22

Family

ID=35451384

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000368A TNSN06368A1 (fr) 2004-05-11 2006-11-10 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines

Country Status (22)

Country Link
US (1) US7307086B2 (fr)
EP (1) EP1746997A4 (fr)
JP (2) JP2007537264A (fr)
KR (1) KR100837019B1 (fr)
CN (1) CN1950085A (fr)
AP (1) AP2314A (fr)
AU (1) AU2005247361B2 (fr)
BR (1) BRPI0510665A (fr)
CA (1) CA2565486A1 (fr)
CR (1) CR8745A (fr)
EA (1) EA011403B1 (fr)
EC (1) ECSP066991A (fr)
GE (1) GEP20084519B (fr)
IL (1) IL179018A0 (fr)
MA (1) MA28580B1 (fr)
MX (1) MXPA06013112A (fr)
NO (1) NO20065678L (fr)
NZ (1) NZ550511A (fr)
TN (1) TNSN06368A1 (fr)
UA (1) UA83917C2 (fr)
WO (1) WO2005115392A2 (fr)
ZA (1) ZA200609013B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115290B (en) 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
KR101235090B1 (ko) 2004-04-13 2013-02-20 인사이트 코포레이션 케모킨 수용체 길항제로서의 피페라지닐피페리딘 유도체
TW200608966A (en) 2004-06-28 2006-03-16 Incyte Corp 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
GEP20094844B (en) 2004-06-28 2009-11-25 Incyte Corp 3-aminocyclopentane carboxamides as modulators of chemokine receptors
WO2007053498A1 (fr) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Composés pouvant être employés en tant qu'antagonistes de ccr2
US20100016289A1 (en) * 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
WO2007053499A2 (fr) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Composés pouvant être employés en tant qu'antagonistes de ccr2
MEP1008A (xx) * 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
PE20081785A1 (es) * 2007-02-19 2009-01-12 Novartis Ag Derivados de ciclohexil-amida del acido aril carboxilico
JP2010540527A (ja) * 2007-09-25 2010-12-24 アボット・ラボラトリーズ ケモカイン受容体拮抗薬としてのオクタヒドロペンタレン化合物
AR080374A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida
US9058753B2 (en) 2012-03-23 2015-06-16 Documotion Research, Inc. Paper, labels made therefrom and methods of making paper and labels
WO2013149376A1 (fr) * 2012-04-02 2013-10-10 Abbott Laboratories Antagonistes de récepteurs de chimiokines
EP2875023B1 (fr) * 2012-07-19 2017-04-05 Janssen Pharmaceutica NV Derives d'octahydrocyclopentapyrrole comme antagonistes de rcc2
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
BR112017024555A2 (pt) 2015-05-21 2018-07-24 Chemocentryx Inc moduladores de ccr2
KR102677442B1 (ko) 2017-09-25 2024-06-20 케모센트릭스, 인크. 케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
MA50423A (fr) 2018-01-08 2020-08-26 Chemocentryx Inc Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2
CN111528842B (zh) * 2020-05-26 2023-01-03 复嶂环洲生物科技(上海)有限公司 基于生理和行为指标的帕金森病症状定量化评估方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU175454B (hu) * 1977-07-25 1980-08-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh predel'nykh i chastichno predel'nykh n-acil-pirrol-2,5-dionov
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JP4176148B2 (ja) 1996-05-20 2008-11-05 帝人ファーマ株式会社 ジアリールアルキル環状ジアミン誘導体およびその治療薬としての使用
BR9814645A (pt) 1997-11-18 2001-07-31 Teijin Ltd Derivados de amina cìclica e seu uso como medicamentos
WO2000069815A1 (fr) 1999-05-13 2000-11-23 Teijin Limited Derives d'amines cycliques ureido-substituees et leur utilisation en tant que medicament
DE60023878T2 (de) 1999-05-18 2006-07-20 Teijin Ltd. Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
KR100667645B1 (ko) 1999-08-04 2007-02-28 데이진 가부시키가이샤 환상 아민 ccr3 길항제
US6410566B1 (en) * 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
CA2419194C (fr) * 2000-08-17 2007-10-16 Lihu Yang Modulateurs cyclopentyles de l'activite du recepteur de la chimiokine
ATE396993T1 (de) * 2002-04-29 2008-06-15 Merck & Co Inc Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
CA2483843A1 (fr) * 2002-04-29 2003-11-13 Merck & Co. Inc. Modulateurs de l'activite des recepteurs des chimiokines a base de tetrahydropyranyl cyclopentyl tetrahydroisoquinoline
JP2006507301A (ja) 2002-10-30 2006-03-02 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体活性のピペリジニルシクロペンチルアリールベンジルアミドモジュレーター
EP1558250A4 (fr) 2002-10-30 2006-11-02 Merck & Co Inc Modulateurs gamma-aminoamides de l'activite de recepteur de chimiokine
CA2503844A1 (fr) 2002-10-30 2004-05-21 Merck & Co., Inc. Modulateur piperidinyl-alpha-aminoamide de l'activite de recepteurs de la chimiokine
CA2502174A1 (fr) 2002-10-30 2004-05-21 Merck & Co., Inc. Modulateurs de l'activite des recepteurs de la chimiokine a base de tetrahydropyranyl-cyclopentyl-benzylamide
AU2003284975B2 (en) 2002-10-30 2009-04-02 Merck Sharp & Dohme Corp. Heteroarylpiperidine modulators of chemokine receptor activity
GEP20115290B (en) 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
AR045875A1 (es) 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
AU2004287416C1 (en) 2003-10-27 2010-09-09 Merck Sharp & Dohme Corp. CCR-2 antagonist salt
UA82917C2 (en) 2003-12-18 2008-05-26 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptor
US20070117797A1 (en) 2004-01-02 2007-05-24 Goble Stephen D Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
WO2005070133A2 (fr) 2004-01-20 2005-08-04 Merck & Co., Inc. Piperidines disubstituees en 2,6, modulatrices de l'activite du recepteur de la chemokine
JP2007519734A (ja) 2004-01-28 2007-07-19 メルク エンド カムパニー インコーポレーテッド アミノシクロペンチルピリドピラジノン系ケモカイン受容体活性調節剤
WO2005110409A2 (fr) 2004-04-26 2005-11-24 Merck & Co., Inc. Modulateurs tetrahydropyranyle cyclopentyle de tetrahydroisoquinoline 1 substituee et 1,1-disubstituee de l'activite des recepteurs de chimiokine

Also Published As

Publication number Publication date
IL179018A0 (en) 2007-03-08
CN1950085A (zh) 2007-04-18
WO2005115392A3 (fr) 2006-02-02
US7307086B2 (en) 2007-12-11
EA011403B1 (ru) 2009-02-27
NO20065678L (no) 2007-02-08
AP2006003787A0 (en) 2006-10-31
AU2005247361A1 (en) 2005-12-08
WO2005115392A8 (fr) 2006-10-05
MA28580B1 (fr) 2007-05-02
US20050267146A1 (en) 2005-12-01
WO2005115392A2 (fr) 2005-12-08
UA83917C2 (en) 2008-08-26
NZ550511A (en) 2010-07-30
AP2314A (en) 2011-10-31
AU2005247361B2 (en) 2011-03-17
KR100837019B1 (ko) 2008-06-10
JP2010254715A (ja) 2010-11-11
ECSP066991A (es) 2006-12-29
EP1746997A2 (fr) 2007-01-31
JP2007537264A (ja) 2007-12-20
BRPI0510665A (pt) 2007-12-04
KR20070007360A (ko) 2007-01-15
GEP20084519B (en) 2008-10-27
ZA200609013B (en) 2008-12-31
EA200601895A1 (ru) 2007-04-27
EP1746997A4 (fr) 2010-12-29
CA2565486A1 (fr) 2005-12-08
MXPA06013112A (es) 2007-02-14
CR8745A (es) 2007-01-31

Similar Documents

Publication Publication Date Title
TNSN06368A1 (fr) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA31147B1 (fr) 4-phenyl-pyrane-3.5-diones ,4-phenyl-thiopyrane-3.5- diones et cyclohexanetriones en tant que nouveaux herbicides
TNSN03143A1 (fr) Ligands de recepteurs de 5-ht et leurs utilisations .
WO2003103584A3 (fr) Imidazopyridines a substitution ether
MA31767B1 (fr) Composes organiques et leurs utilisations
EP1501507A4 (fr) Modulateurs tetrahydropyranyl cyclopentyl tetrahydropyridopyridine de l'activite des recepteurs de chimiokine
TNSN06188A1 (fr) Derives de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de recepteurs de chimiokines
MA33155B1 (fr) Composes organiques et leurs utilisations
TNSN05190A1 (fr) DERIVES DE PYRAZOLO [1,5-a][1,3,5] TRIAZINE SERVANT DE LIGANDS DES RECEPTEURS DE CANNABINOIDES
TNSN06210A1 (fr) Nitro-oxydérivés de prostaglandines
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
NO20071476L (no) Antidiuretiske midler.
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
MA33334B1 (fr) Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
TNSN06129A1 (fr) Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations
TNSN06037A1 (fr) Formulations liquides
MA29723B1 (fr) Composes
MA30485B1 (fr) Aminothiazoles et leurs utilisations
MA27501A1 (fr) Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3